Clinical Trials Logo

Lymph Node Metastasis clinical trials

View clinical trials related to Lymph Node Metastasis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06264167 Not yet recruiting - Clinical trials for Ultrasound Therapy; Complications

NODE (groiN ultrasOunD cancEr)

NODE
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This study is an open label, prospective, experimental, randomised clinical trial. The primary aim of this study is to determine whether it is feasible to randomise vulvar cancer patients into one of two treatment arms:1) surgical groin node dissection (as delivered though either a sentinel node biopsy or inguinofemoral lymph node dissection (IFL), or 2) serial high-resolution bilateral groin ultrasound surveillance and clinical examination every 2 months.

NCT ID: NCT06252129 Not yet recruiting - Lung Cancer Clinical Trials

Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

Start date: February 2024
Phase: N/A
Study type: Interventional

Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.

NCT ID: NCT05375526 Not yet recruiting - Ovarian Cancer Clinical Trials

Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Epithelial ovarian cancer (EOC) remains the tumour with the most unfavourable prognosis within the field of gynaecological oncology. The incidence of ovarian cancer in the Netherlands in 2008 was 14.5 per 100.000, with 12.3 deaths per 100.000. In the US in 2007 the incidence was 13.0 per 100.000 and there were 8.2 deaths per 100.000. The high mortality rate is partially due to the fact that approximately 75% of patients is diagnosed with advanced stage EOC. The remaining 25% of patients are diagnosed in an early stage, which require a complete surgical staging procedure including pelvic and para-aortic lymphadenectomy. Although this lymphadenectomy is standard-of-care, it leads to significant morbidity in these patients. Mainly direct postoperative complications such as infection, repeat surgery and early death have been reported. Also, long-term complications such as lymph cysts or lymphedema have been described. A potential method to reduce this morbidity and mortality, as already been described in other cancers such as breast cancer and vulvar cancer, is utilizing a sentinel lymph node (SLN) technique. By identifying and resecting the SLN, the patient is potentially spared form lymphadenectomy.

NCT ID: NCT05336643 Not yet recruiting - Rectal Cancer Clinical Trials

Radioisotope and Fluorescence Guidance in Rectal Cancer

Start date: January 2023
Phase: N/A
Study type: Interventional

A study to investigate if pelvic side wall lymph nodes that remain after neo-adjuvant chemoradiotherapy can be identified intraoperatively using dual radioisotope and fluorescence guidance.